Recently, we reiterated our Neutral recommendation on
) with a target price of $75.00. Haemonetics began fiscal 2013 on a
disappointing note with both adjusted EPS of 55 cents and revenues
of $176.5 million lagging the Zacks Consensus Estimates.
After witnessing a challenging scenario during most of last
year, Plasma, accounting for 44% of disposables, is now on the path
to recovery. Although plasma growth was adversely affected by
higher inventory purchase by the Japan Red Cross Society ('JRC') in
the last quarter ahead of a system conversion, we are impressed to
note that growth in North America returned to mid-single digits.
The company also made commendable progress with respect to contract
extensions as 98% of this business is covered through the third
quarter of fiscal 2015.
Haemonetics remains focused on blood management solutions in
order to provide better services to customers. During the reported
quarter, the company added 8 new IMPACT accounts, resulting in a
total of 266. This is encouraging as sales derived from the IMPACT
accounts has been much higher than non-IMPACT accounts during the
quarter - for both blood centers ($537,000 versus $82,000) and
hospitals ($100,000 in sales, almost three times more than a
non-IMPACT account). Revenues from Diagnostics (consisting
principally of TEG or Thrombelastograph Hemostasis Analyzer)
increased, driven by the deeper penetration of IMPACT (blood
management system) accounts in North America and significant growth
We believe that after the acquisition of the transfusion
medicine business of
) for $551 million, Haemonetics will be able to enter the $1.2
billion whole blood collection market. Manual whole blood
collection accounts for the vast majority of the nearly 60 million
red blood cells collection procedures performed annually worldwide.
The acquired business generated approximately $210 million in
annual revenues spread across the Americas ($136 million), Europe
($52 million) and Asia ($22 million) and 15% of global unit market
share. We believe that the entry to this attractive market should
drive the company's top line going ahead.
We are also impressed by emerging markets being an area of key
focus for Haemonetics. Sales momentum from this region continued
and increased by 16% during the reported quarter (to $30 million in
revenues). We also note that the robust growth of Diagnostics is
based on the 70% growth of TEG revenues in China, which is
penetrating deeper into the field of interventional cardiology.
Over the next five years, business from China is slated for a CAGR
of 20−25% driven by sales from platelets, cell salvage and TEG.
However, margins continued to remain under pressure due to
increased investments associated with global growth initiatives,
expansion in emerging markets and infrastructure development.
Besides, the uncertain economic scenario continues to pose a
challenge for Haemonetics.
The stock carries a Zacks #3 Rank ('Hold') in the short
HAEMONETICS CP (HAE): Free Stock Analysis
PALL CORP (PLL): Free Stock Analysis Report
To read this article on Zacks.com click here.